Mid
C
CAPRAI Stock Diagnostic Report
Capricor jumps as study shows longer-term effects of deramiocel
Capricor (CAPR) surged on research data showing the long-term effects of Deramiocel.
View Source Article ↗AI CATALYST SCORE80 / 100Score computed by Sentinel V12
REFERENCE PRICE$8.57Reference entry price at analysis time
01
FUNDAMENTALS
Financial & Fundamental Analysis
The pipeline value may be highlighted by the confirmation of long-term efficacy of deramiocel, a Duchenne Muscular Dystrophy (DMD) therapeutic, but a time lag exists in its reflection in short-term financial performance.
02
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The disclosure of long-term data for deramiocel at the 31st Annual Meeting of the World Muscle Society has rekindled investor interest.